Insys Therapeutics Inc (NASDAQ:INSY) Director Steven J. Meyer purchased 8,000 shares of the business’s stock in a transaction on Thursday, May 18th. The stock was purchased at an average cost of $12.21 per share, with a total value of $97,680.00. Following the completion of the acquisition, the director now owns 52,083 shares in the company, valued at $635,933.43. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Insys Therapeutics Inc (NASDAQ:INSY) traded up 0.91% during mid-day trading on Thursday, hitting $12.20. 373,849 shares of the stock traded hands. Insys Therapeutics Inc has a 12 month low of $8.70 and a 12 month high of $19.96. The company’s 50 day moving average is $10.95 and its 200 day moving average is $10.87. The company’s market cap is $879.93 million.

Insys Therapeutics (NASDAQ:INSY) last issued its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. Insys Therapeutics had a net margin of 8.71% and a return on equity of 9.39%. The firm had revenue of $35.92 million during the quarter, compared to analyst estimates of $37.78 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. Insys Therapeutics’s revenue for the quarter was down 40.5% on a year-over-year basis. On average, analysts expect that Insys Therapeutics Inc will post ($0.48) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

ILLEGAL ACTIVITY WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/18/steven-j-meyer-acquires-8000-shares-of-insys-therapeutics-inc-insy-stock.html.

Institutional investors have recently modified their holdings of the company. Norges Bank bought a new position in shares of Insys Therapeutics during the fourth quarter worth $3,408,000. Credit Agricole S A raised its position in shares of Insys Therapeutics by 62.5% in the fourth quarter. Credit Agricole S A now owns 312,000 shares of the specialty pharmaceutical company’s stock worth $2,870,000 after buying an additional 120,000 shares in the last quarter. Scopia Capital Management LP bought a new position in shares of Insys Therapeutics during the third quarter worth $107,631,000. Bowling Portfolio Management LLC bought a new position in shares of Insys Therapeutics during the first quarter worth $655,000. Finally, BlackRock Inc. raised its position in shares of Insys Therapeutics by 23.4% in the third quarter. BlackRock Inc. now owns 55,675 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 10,570 shares in the last quarter. Hedge funds and other institutional investors own 45.21% of the company’s stock.

Several analysts have recently weighed in on INSY shares. Oppenheimer Holdings Inc. restated a “” rating on shares of Insys Therapeutics in a research report on Thursday, January 19th. Zacks Investment Research cut shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 23rd. Jefferies Group LLC restated a “buy” rating and set a $16.00 price objective on shares of Insys Therapeutics in a research report on Thursday, March 16th. Royal Bank of Canada set a $16.00 price objective on shares of Insys Therapeutics and gave the company a “buy” rating in a research report on Monday, March 27th. Finally, Piper Jaffray Companies cut shares of Insys Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $20.00 to $10.00 in a research report on Wednesday, May 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $13.50.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

5 Day Chart for NASDAQ:INSY

Receive News & Ratings for Insys Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.